Icon

REVUFORJ - (25MG, 110MG, 160MG)

REVUMENIB CITRATE None
25MG, 110MG, 160MG
Less Than $1000 mn
None None
None None
None None
REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
Yes
REVUFORJ Patent 1 Patent 2
*** *********

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.